Sandoz Matches Teva On US Rifaximin Launch Date
Company Had Been Sued In October Last Year
Executive Summary
Sandoz has joined a fellow major generics player, Teva’s Actavis, in settling itself out of litigation with Bausch Health over Xifaxan 550mg tablets in the US. The two settlement agreements contain key similarities and differences.
You may also be interested in...
US Court Shoots Down Norwich In ‘Unprecedented’ Xifaxan ‘Skinny Label’ Claim
Coming down heavily on Norwich Pharmaceuticals, a US district court has denied the US-based generics firm’s bid for relief post-judgment in a case involving the “hotly disputed” issue of skinny label ANDA products.
Lupin Turns Up Heat With Bausch Brands Acquisition, Perforomist Generic Launch
Two acquisitions of brands in as many months, Lupin has stepped up its game in the Americas. A buyout of nine established Bausch Health brands follows rights to two from Sunovion. While it awaits news on generic(g) Spiriva, the launch of gPerforomist will help expand Lupin’s respiratory franchise
Lupin Turns Up Heat With Bausch Brands Acquisition, Perforomist Generic Launch
Two acquisitions of brands in as many months, Lupin has stepped up its game in the Americas. A buyout of nine established Bausch Health brands follows rights to two from Sunovion. While it awaits news on generic(g) Spiriva, the launch of gPerforomist will help expand Lupin’s respiratory franchise